Repotrectinib has shown significant efficacy in the treatment of NTRK gene fusion positive solid tumors, and its storage should be controlled at 20-25 ° C, allowing for brief fluctuations to 15-30 ° C. The drug should be noted for adverse reactions such as central nervous system effects and liver toxicity, and should be carefully adjusted for special populations.

1. Treatment effect

(1) Clinical effectiveness

Riptinib has been shown to significantly inhibit tumor progression in NTRK positive solid tumor patients aged 12 years and above, especially in locally advanced or metastatic cases.

(2) Pharmacokinetic advantages

After taking on an empty stomach, the peak blood drug value is reached 2-3 hours later, with a bioavailability of 45.7%. The half-life at steady state is about 40.3 hours, and the duration of the drug effect is relatively long.

2 Temperature requirements

(1) Conventional storage

It is recommended to store the drug in an environment between 20 ° C and 25 ° C to ensure its stability.

(2) Short term fluctuations

During transportation or temporary storage, a temperature range of 15 ° C to 30 ° C is allowed, but the cumulative time should not exceed 24 hours.

3 Packaging Management

(1) Original packaging preservation

Always keep the desiccant in the original bottle and tighten the bottle cap to prevent moisture.

(2) Handling after opening

If it is a packaged preparation, it must be used up within the specified period after opening (usually within 3 months).

4 Environmental Control

(1) Light avoidance requirements

When storing, it should be kept away from direct light sources, and it is recommended to keep the outer box of the medicine out of light.

(2) Humidity control

The relative humidity should be maintained below 60%, and desiccants should be used in humid environments.

5 Medication Safety Tips

(1) Adverse reaction management

Common central nervous system symptoms such as dizziness and ataxia should be avoided while driving during medication; Regular monitoring of liver function and respiratory symptoms is required.

(2) Special populations

Women of childbearing age should use non hormonal contraception and suspend feeding during lactation; Elderly patients do not need to adjust their dosage, but monitoring needs to be strengthened.